Societas medicinae technologiae technologiae technologiae ad evolutionem promovendam intendit pro diagnosi cancri, hodie novos eventus investigationis annuntiavit. Investigatio clinica cancer hepatis magnam potentiam novae DNA methylationi-basoris LAM demonstravit ad carcinoma hepatocellulares (HCC) Deprehensio sensus 95% et proprietas est 97.5%.
In hoc studio, generis specimina 130 subditorum collecta, in iis: 60 subjecta praecognita carcinomate hepatocellulari (scaena I ad IV), subditi sine morbo hepatis 30, 10 subditi benigno iecoris morbo praecogniti et 30 subditi carcinomate praecogniti, cancer colorectalis. vel cancer pulmonis. DNA extractum est ex sample, DNA cum bisulfito mutatus est, et DNA methylation quanta usus erat in suggestu IvyGene. Peracta notitia collectionis et analysi omnium exemplorum, exempla excaecant ad calculandum faciendum.
A total of 57 of the 60 samples taken from patients with hepatocellular carcinoma were correctly identified, with an overall calculated sensitivity of 95%. The sensitivity difference between detecting stage I and stage IV hepatocellular carcinoma was small (range 89% to 100%). Of the samples taken from cancer patients other than liver cancer, 90% of breast cancer samples, 80% of colorectal cancer samples, and 90% of lung cancer samples were correctly identified as non-liver cancer, and the total calculated specificity was 87%.
